Polygenic predisposition to venous thromboembolism is associated with increased COVID-19 positive testing rates

Jessica Minnier, Jennifer E. Huffman, Lina Gao, Jacob Joseph, Emily S. Wan, Wen‐Chih Wu, Ayako Suzuki, Gita A. Pathak, Renato Polimanti, Mehrdad Arjomandi, Kyong‐Mi Chang, Helene Garcon, Anurag Verma, Yuk‐Lam Ho, James B. Meigs, Kelly Cho, Robert A. Bonomo, Bryan R. Gorman, Saiju Pyarajan, Elise Gatsby, Nallakkandi Rajeevan, Kristine E. Lynch, Julie A. Lynch, Seyedeh M. Zekavat, Pradeep Natarajan, Cecelia J. Madison, Jin Zhou, Darshana Jhala, Curtis J. Donskey, John E. McGeary, Peter D. Reaven, Yan V. Sun, Mat Freiberg, Joel Gelernter, J M Petersen, Adriana M. Hung, Rose D. L. Huang, Ravi Madduri, Sharvari Dalal, Quinn S. Wells, Katherine P. Liao, Peter W.f. Wilson, Philip S. Tsao, Christopher J. O’Donnell, John Michael Gaziano, Richard L. Hauger, Sudha K. Iyengar, Shiuh‐Wen Luoh, Shiuh-Wen LuohmedRxiv 2022 · DOI

Abstract

Genetic predisposition to venous thromboembolism (VTE) may influence both the susceptibility to COVID-19 infection and its subsequent clinical course. Using data from the Million Veteran Program (MVP), this study evaluated the associations between polygenic VTE risk, Factor V Leiden (FVL), and the prothrombin gene 3’-UTR mutation (F2 G20210A) with COVID-19 outcomes. Among 108,437 European American participants tested for COVID-19, a higher Polygenic Risk Score (PRS) for VTE was significantly associated with a positive test result in individuals without the FVL mutation (OR 1.05 per SD). However, genetic risk did not correlate with disease severity. These findings suggest that coagulation pathways may be involved in the initial stages of SARS-CoV-2 infection.

Introduction

Throughout the pandemic, "immunothrombosis"—the complex interplay between the immune response and the blood clotting system—has been recognized as a hallmark of severe COVID-19. While much research has characterized thrombosis as a late-stage complication of the disease, the potential for baseline prothrombotic states to influence infection risk remains less understood.

This study investigates whether a person's baseline genetic risk for clotting influences their susceptibility to catching the virus or the severity of the resulting disease. By examining both common monogenic mutations (like Factor V Leiden) and a broad Polygenic Risk Score (PRS), the research team sought to understand if the machinery of coagulation is involved in the initial infection process rather than just the inflammatory aftermath.

Methods

The study employed a prospective cohort design using the Million Veteran Program (MVP) database, one of the world's largest gene-health resources. The researchers focused on a cohort of 464,961 participants of European ancestry, identifying a subgroup of 108,437 individuals who underwent COVID-19 testing within the VA healthcare system between March 2020 and June 2021.

The genetic analysis utilized:

  • Polygenic Risk Score (PRS): A weighted score derived from 297 genetic variants previously validated to predict VTE risk.
  • Monogenic Markers: Specific testing for the Factor V Leiden (FVL) mutation (rs6025) and the Prothrombin G20210A mutation (rs1799963).

Statistical associations were assessed using Firth logistic regression, adjusting for age, sex, genetic principal components, and the use of outpatient anticoagulation medications in the two years prior to testing.

Key Results

Infection Susceptibility vs. Severity

The most striking finding was that a higher PRS for VTE was associated with a higher rate of positive COVID-19 tests. In individuals without the Factor V Leiden mutation (F5 wild type), each standard deviation increase in the PRS was associated with a 5% increase in the odds of testing positive (OR 1.05; 95% CI [1.02-1.07]).

Surprisingly, genetic predisposition to VTE did not predict COVID-19 severity (defined by ICU admission or death). This suggests that while clotting genetics might facilitate the virus's ability to establish an infection, other factors—such as the host's inflammatory response or viral load—likely drive the progression to severe clinical outcomes.

Epistatic Interactions

The link between the PRS and positive testing was significant in wild-type individuals but disappeared in FVL carriers (OR 0.97). This suggests a potential epistatic effect, where the strong biological signal from the FVL mutation masks or overrides the more subtle influence of the polygenic background regarding infection susceptibility.

Post-COVID Sequelae

Testing positive for COVID-19 was associated with significantly increased risks for several conditions within one year of the test, regardless of genetic background:

  • Venous Thromboembolism (VTE): OR 1.37
  • Acute Myocardial Infarction (MI): OR 1.16
  • Dementia: OR 1.49

Clinical Stratification

The PRS for VTE successfully risk-stratified FVL carriers regarding their actual VTE risk. FVL carriers in the top 20% of the PRS had a twofold increase in VTE risk compared to those in the bottom 20%, demonstrating the clinical utility of combining monogenic and polygenic data for personalized risk assessment.

Discussion and Limitations

The association between VTE genetic risk and COVID-19 positivity suggests that a "prothrombotic milieu" might facilitate the early stages of viral entry or establishment. This points toward a potential role for coagulation factors in the initial infection process that warrants further mechanistic study.

Several limitations apply to these findings. The study was limited to participants of European ancestry to ensure PRS accuracy, and future work must validate these results in more diverse populations. Additionally, the study period concluded before the widespread availability of vaccines and the emergence of the Delta and Omicron variants. Finally, while the statistical link is clear, the exact molecular mechanism—how specific clotting factors might assist viral entry—requires laboratory investigation.

Conclusion

Increased genetic propensity for VTE is associated with increased COVID-19 positive testing rates in the MVP cohort. These results suggest that coagulation pathways play a role in the initial steps of COVID-19 infection and underscore the value of polygenic risk scores in refining the risk profile of individuals with known monogenic mutations.

Summary updated

Abstract

Abstract Genetic predisposition to venous thrombosis may impact COVID-19 infection and its sequelae. Participants in the ongoing prospective cohort study, Million Veteran Program (MVP), who were tested for COVID-19, with European ancestry, were evaluated for associations with polygenic venous thromboembolic risk, Factor V Leiden mutation (FVL) (rs6025) and prothrombin gene 3’ -UTR mutation (F2 G20210A)(rs1799963), and their interactions. Logistic regression models assessed genetic associations with VTE diagnosis, COVID-19 (positive) testing rates and outcome severity (modified WHO criteria), and post-test conditions, adjusting for outpatient anticoagulation medication usage, age, sex, and genetic principal components. 108,437 out of 464,961 European American MVP participants were tested for COVID-19 with 9786 (9%) positive. PRS(VTE), FVL, F2 G20210A were not significantly associated with the propensity of being tested for COVID-19. PRS(VTE) was significantly associated with a positive COVID-19 test in F5 wild type (WT) individuals (OR 1.05; 95% CI [1.02-1.07]), but not in FVL carriers (0.97, [0.91-1.94]). There was no association with severe outcome for FVL, F2 G20210A or PRS(VTE). Outpatient anticoagulation usage in the two years prior to testing was associated with worse clinical outcomes. PRS(VTE) was associated with prevalent VTE diagnosis among both FVL carriers or F5 wild type individuals as well as incident VTE in the two years prior to testing. Increased genetic propensity for VTE in the MVP was associated with increased COVID-19 positive testing rates, suggesting a role of coagulation in the initial steps of COVID-19 infection. Key Points Increased genetic predisposition to venous thrombosis is associated with increased COVID-19 positive testing rates. PRS for VTE further risk stratifies factor V Leiden carriers regarding their VTE risk.
BibTeX
@misc{minnier2022polygenic,
  author = {Jessica Minnier and Jennifer E. Huffman and Lina Gao and Jacob Joseph and Emily S. Wan and Wen‐Chih Wu and Ayako Suzuki and Gita A. Pathak and Renato Polimanti and Mehrdad Arjomandi and Kyong‐Mi Chang and Helene Garcon and Anurag Verma and Yuk‐Lam Ho and James B. Meigs and Kelly Cho and Robert A. Bonomo and Bryan R. Gorman and Saiju Pyarajan and Elise Gatsby and Nallakkandi Rajeevan and Kristine E. Lynch and Julie A. Lynch and Seyedeh M. Zekavat and Pradeep Natarajan and Cecelia J. Madison and Jin Zhou and Darshana Jhala and Curtis J. Donskey and John E. McGeary and Peter D. Reaven and Yan V. Sun and Mat Freiberg and Joel Gelernter and J M Petersen and Adriana M. Hung and Rose D. L. Huang and Ravi Madduri and Sharvari Dalal and Quinn S. Wells and Katherine P. Liao and Peter W.F. Wilson and Philip S. Tsao and Christopher J. O’Donnell and John Michael Gaziano and Richard L. Hauger and Sudha K. Iyengar and Shiuh‐Wen Luoh and Shiuh-Wen Luoh},
  title = {{Polygenic predisposition to venous thromboembolism is associated with increased COVID-19 positive testing rates}},
  year = {2022},
  doi = {10.1101/2022.01.29.22270094},
  howpublished = {medRxiv},
}
Figure